Evidence map›Paper›PMID 30803452›Full record

ArticleJournal of ovarian research2019

Magnetic resonance imaging findings for discriminating clear cell carcinoma and endometrioid carcinoma of the ovary.

Sachiko Morioka, Ryuji Kawaguchi, Yuki Yamada, Kana Iwai, Chiharu Yoshimoto, Hiroshi Kobayashi

Open access · goldAbstract readComparative Study
In one paragraph

Article in Journal of ovarian research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Current update on malignant epithelial ovarian tumors.Abdominal radiology (New York) · 2021
    Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sachiko MoriokaDepartment of Obstetrics and Gynecology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan. morioka.sac@gmail.com.ORCID http://orcid.org/0000-0002-1113-2573
Ryuji KawaguchiDepartment of Obstetrics and Gynecology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Yuki YamadaDepartment of Obstetrics and Gynecology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Kana IwaiDepartment of Obstetrics and Gynecology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Chiharu YoshimotoDepartment of Obstetrics and Gynecology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Hiroshi KobayashiDepartment of Obstetrics and Gynecology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Nara Medical University · JPYao Tokushukai General Hospital · JP

Funding

Tohoku Bureau of Economy Tohoku 1607028
6 · The paper itself

Abstract

backgroundCommon cancerous histological types associated with endometriosis are clear cell carcinoma (CCC) and endometrioid carcinoma (EC). CCC is regarded as an aggressive, chemoresistant histological subtype. Magnetic resonance imaging (MRI) offers some potential advantages to diagnose ovarian tumors compared with ultrasonography or computed tomography. This study aimed to identify MRI features that can be used to differentiate between CCC and EC.

methodsWe searched medical records of patients with ovarian cancers who underwent surgical treatment at Nara Medical University Hospital between January 2008 and September 2018; we identified 98 patients with CCC or EC who had undergone preoperative MRI. Contrasted MRI scans were performed less than 2 months before surgery. Patients were excluded from the study if they had no pathology, other pathological subtype of epithelial ovarian cancer, and/or salvage treatment for recurrence and metastatic ovarian cancer at the time of study initiation. Clinically relevant variables that were statistically significant by univariate analysis were selected for subsequent multivariate regression analysis to identify independent factors to distinguish CCC from EC.

resultsMRI of CCC and EC showed a large cystic heterogeneous mixed mass with mural nodules protruding into the cystic space. Univariate logistic regression analysis revealed that the growth pattern (broad-based nodular structures [multifocal/concentric sign] or polypoid structures [focal/eccentric sign]), surface irregularity (a smooth/regular surface or a rough/irregular/lobulated surface), "Width" of mural nodule, "Height-to-Width" ratio (HWR), and presence of preoperative ascites were factors that significantly differed between CCC and EC. In the multivariate logistic regression analysis, the growth pattern of the mural nodule (odds ratio [OR] = 0.69, 95% confidence interval [CI]: 0.013-0.273, p = 0.0004) and the HWR (OR = 3.71, 95% CI: 1.128-13.438, p = 0.036) were independent predictors to distinguish CCC from EC.

conclusionsIn conclusion, MRI data showed that the growth pattern of mural nodules and the HWR were independent factors that could allow differentiation between CCC and EC. This finding may be helpful to predict patient prognosis before operation.

Indexed as

Magnetic Resonance ImagingAdenocarcinoma, Clear CellAdultAgedAged, 80 and overCarcinoma, EndometrioidContrast MediaDiagnosis, DifferentialEndometriosisFemaleHumansMiddle AgedOvarian NeoplasmsOvaryPreoperative PeriodPrognosisContrast MediaCarcinoma, Endometrioid, Endometriosis, Logistic Models, Ascites, Pathology, Surgical, Adenocarcinoma, Clear Cell, Multivariate Analysis, Magnetic Resonance Imaging

Identifiers

PMID30803452
PMCPMC6388492
OpenAlexW2929921937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.